AllianceBernstein’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-94,099
| Closed | -$5.63M | – | 3216 |
|
|
2019
Q4 | $5.63M | Buy |
94,099
+34,999
| +59% | +$1.31M | ﹤0.01% | 1366 |
|
|
2019
Q3 | $1.66M | Buy |
59,100
+1,100
| +2% | +$37.5K | ﹤0.01% | 2026 |
|
|
2019
Q2 | $2.2M | Buy |
58,000
+18,100
| +45% | +$695K | ﹤0.01% | 1919 |
|
|
2019
Q1 | $1.56M | Sell |
39,900
-177,400
| -82% | -$5.09M | ﹤0.01% | 2036 |
|
|
2018
Q4 | $4.63M | Sell |
217,300
-442,981
| -67% | -$11.4M | ﹤0.01% | 1330 |
|
|
2018
Q3 | $26.1M | Buy |
660,281
+189,825
| +40% | +$7.08M | 0.02% | 714 |
|
|
2018
Q2 | $18M | Buy |
470,456
+133,101
| +39% | +$4.93M | 0.01% | 807 |
|
|
2018
Q1 | $10.1M | Sell |
337,355
-118,868
| -26% | -$4.02M | 0.01% | 935 |
|
|
2017
Q4 | $14.3M | Sell |
456,223
-151,572
| -25% | -$4.16M | 0.01% | 860 |
|
|
2017
Q3 | $17M | Sell |
607,795
-32,859
| -5% | -$714K | 0.01% | 819 |
|
|
2017
Q2 | $12.3M | Buy |
640,654
+153,617
| +32% | +$2.45M | 0.01% | 877 |
|
|
2017
Q1 | $8.3M | Sell |
487,037
-46,221
| -9% | -$748K | 0.01% | 982 |
|
|
2016
Q4 | $9.74M | Sell |
533,258
-32,580
| -6% | -$563K | 0.01% | 923 |
|
|
2016
Q3 | $10.1M | Buy |
+565,838
| New | +$8.59M | 0.01% | 897 |
|
AllianceBernstein's BOLD Position: Q1 2020 in Review
AllianceBernstein sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 94,099 shares — an estimated $5.63M sold.
AllianceBernstein first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $26.1M in Q3 2018. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- AllianceBernstein reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- AllianceBernstein sold 94,099 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $5.63M.
- AllianceBernstein first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- AllianceBernstein's Audentes Therapeutics, Inc position peaked at $26.1M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on AllianceBernstein's 13F filing for Q1 2020, filed 14 May 2020.